Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis

Sex hormones promote potent immunoregulatory effects on autoimmune diseases, including multiple sclerosis (MS). Our previous studies demonstrated a critical role for regulatory B cells in mediating estrogen (17β-estradiol, E2)-mediated protection against experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, leading to elevated numbers of IL-10 secreting CD1dhiCD5+B regulatory cells (Bregs) in wild type mice. The current study evaluated estrogen effects on regulatory B cells and resident CNS microglia during EAE and demonstrates for the first time an E2-dependent induction of multiple regulatory B cell markers indicative of IL-10 dependent as well as IFN-γ dependent pathways. Moreover, although E2 pretreatment of female EAE mice inhibited the infiltration of pro-inflammatory immune cells into the CNS compared with sham pretreated mice, it enhanced the frequency of regulatory B cells and M2 microglia in the CNS. Our study suggests that estrogen has a broad effect on the development of regulatory B cells during EAE, which in turn could promote neuroprotection in the CNS.

Role for microglia in sex differences after ischemic stroke: importance of M2

Inflammation plays a critical role in the pathogenesis of ischemic stroke. This process depends, in part, upon proinflammatory factors released by activated resident central nervous system (CNS) microglia (MG). Previous studies demonstrated that transfer of IL-10(+) B-cells reduced infarct volumes in male C57BL/6 J recipient mice when given 24 h prior to or therapeutically at 4 or 24 h after experimental stroke induced by 60 min middle cerebral artery occlusion (MCAO). The present study assesses possible sex differences in immunoregulation by IL-10(+) B-cells on primary male vs. female MG cultured from naïve and ischemic stroke-induced mice. Thus, MG cultures were treated with recombinant (r)IL-10, rIL-4 or IL-10(+) B-cells after lipopolysaccharide (LPS) activation and evaluated by flow cytometry for production of proinflammatory and anti-inflammatory factors. We found that IL-10(+) B-cells significantly reduced MG production of TNF-α, IL-1β and CCL3 post-MCAO and increased their expression of the anti-inflammatory M2 marker, CD206, by cell-cell interactions. Moreover, MG from female vs. male mice had higher expression of IL-4 and IL-10 receptors and increased production of IL-4, especially after treatment with IL-10(+) B-cells. These findings indicate that IL-10-producing B-cells play a crucial role in regulating MG activation, proinflammatory cytokine release and M2 phenotype induction, post-MCAO, with heightened sensitivity of female MG to IL-4 and IL-10. This study, coupled with our previous demonstration of increased numbers of transferred IL-10(+) B-cells in the ischemic hemisphere, provide a mechanistic basis for local regulation by secreted IL-10 and IL-4 as well as direct B-cell/MG interactions that promote M2-MG.

Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice

Clinical improvement during pregnancy in multiple sclerosis (MS) patients suggests that sex hormones exert potent regulatory effects on autoimmune function. Our previous studies demonstrated that estrogen- (17β-estradiol; E2) mediated protection against experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, hinges on the B cells, leading to elevated numbers of IL-10 secreting CD1d(hi)CD5(+) B regulatory cells (Bregs) in wild type mice. Our data show that co-administration of E2 and IL-10(+) B cells ameliorates EAE disease severity and limits CNS infiltrating leukocytes in B cell deficient mice. Additionally, treatment with E2 and Bregs reduces demyelination and dramatically decreases the proportion of CD11b(+)CD45(hi) activated microglia/macrophages found in the CNS of immunized animals compared to vehicle, E2 or Breg cells alone. Furthermore, mice given E2 and Bregs exhibit increased numbers of peripheral programmed death-1 positive CD4(+)Foxp3(+) regulatory T cells (Tregs) and up-regulation of programmed death receptor-ligand-1 and CD80 expression on monocytes. Our study suggests IL-10 producing Bregs have powerful therapeutic potential as an agent against EAE when augmented with E2 treatment.

PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation

BACKGROUND AND PURPOSE

Both pathogenic and regulatory immune processes are involved in the middle cerebral artery occlusion (MCAO) model of experimental stroke, including interactions involving the programmed death 1 (PD-1) receptor and its 2 ligands, PD-L1 and PD-L2. Although PD-1 reduced stroke severity, PD-L1 and PD-L2 appeared to play pathogenic roles, suggesting the use of anti-PD-L monoclonal antibody therapy for MCAO.

METHODS

Male C57BL/6 mice were treated with a single dose of anti-PD-L1 monoclonal antibody 4 hours after MCAO and evaluated for clinical, histological and immunologic changes after 96 hours of reperfusion.

RESULTS

Blockade of the PD-L1 checkpoint using a single injection of 200 μg anti-PD-L1 monoclonal antibody given intravenously 4 hours after occlusion significantly reduced MCAO infarct volumes and improved neurological outcomes after 96 hours of reperfusion. Treatment partially reversed splenic atrophy and decreased central nervous system infiltrating immune cells concomitant with enhanced appearance of CD8(+) regulatory T cells in the lesioned central nervous system hemisphere.

CONCLUSIONS

This study demonstrates for the first time the beneficial therapeutic effects of PD-L1 checkpoint blockade on MCAO, thus validating proposed mechanisms obtained in our previous studies using PD-1- and PD-L-deficient mice. These results provide strong support for the use of available humanized anti-PD-L1 antibodies for treatment of human stroke subjects.

Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells

Clinical stroke induces inflammatory processes leading to cerebral and splenic injury and profound peripheral immunosuppression. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that transfer of IL-10(+) B-cells reduced infarct volume in male C57BL/6J (wild-type, WT) recipient mice when given 24 h prior to or 4 h after middle cerebral artery occlusion (MCAO). The purpose of this study was to determine if passively transferred IL-10(+) B-cells can exert therapeutic and immunoregulatory effects when injected 24 h after MCAO induction in B-cell-sufficient male WT mice. The results demonstrated that IL-10(+) B-cell treated mice had significantly reduced infarct volumes in the ipsilateral cortex and hemisphere and improved neurological deficits vs. Vehicle-treated control mice after 60 min occlusion and 96 h of reperfusion. The MCAO-protected B-cell recipient mice had less splenic atrophy and reduced numbers of activated, inflammatory T-cells, decreased infiltration of T-cells and a less inflammatory milieu in the ischemic hemispheres compared with Vehicle-treated control mice. These immunoregulatory changes occurred in concert with the predominant appearance of IL-10-secreting CD8(+)CD122(+) Treg cells in both the spleen and the MCAO-affected brain hemisphere. This study for the first time demonstrates a major neuroprotective role for IL-10(+) B-cells in treating MCAO in male WT mice at a time point well beyond the ~4 h tPA treatment window, leading to the generation of a dominant IL-10(+)CD8(+)CD122(+) Treg population associated with spleen preservation and reduced CNS inflammation.

IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice

Women with multiple sclerosis (MS) often experience clinical improvement during pregnancy, indicating that sex hormones might have therapeutic effects in MS. Our previous studies have demonstrated that B cells and PD-L1 are crucial for E2 (17β-estradiol)-mediated protection against experimental autoimmune encephalomyelitis (EAE). We here demonstrate that the transfer of IL-10(+) B cells into E2-treated PD-L1(-/-) mice after EAE induction could partially restore E2-mediated protection and decrease the frequency of pro-inflammatory cells in the CNS compared to E2/saline treated PD-L1(-/-) mice. Hence, co-administration of IL-10(+) B cells and E2 might have a powerful therapeutic potential for treatment of EAE.

Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice

We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b(+)CD45(hi)) and CD3(+) T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke

Stroke outcome is worsened by the infiltration of inflammatory immune cells into ischemic brains. Our recent study demonstrated that PD-L1- and to a lesser extent PD-L2-deficient mice had smaller brain infarcts and fewer brain-infiltrating cells vs. wild-type (WT) mice, suggesting a pathogenic role for PD-ligands in experimental stroke. We sought to ascertain PD-L1 and PD-L2-expressing cell types that affect T-cell activation, post-stroke in the context of other known co-stimulatory molecules. Thus, cells from male WT and PD-L-deficient mice undergoing 60 min of middle cerebral artery occlusion (MCAO) followed by 96 h of reperfusion were treated with neutralizing antibodies to study co-stimulatory and co-inhibitory interactions between CD80, cytotoxic T-lymphocyte antigen-4 (CTLA-4), PD-1, and PD-Ls that regulate CD8⁺ and CD4⁺ T-cell activation. We found that antibody neutralization of PD-1 and CTLA-4 signaling post-MCAO resulted in higher proliferation in WT CD8⁺ and CD4⁺ T-cells, confirming an inhibitory role of PD-1 and CTLA-4 on T-cell activation. Also, CD80/CD28 interactions played a prominent regulatory role for the CD8⁺ T-cells and the PD-1/PD-L2 interactions were dominant in controlling the CD4⁺ T-cell responses in WT mice after stroke. A suppressive phenotype in PD-L1-deficient mice was attributed to CD80/CTLA-4 and PD-1/PD-L2 interactions. PD-L2 was crucial in modulating CD4⁺ T-cell responses, whereas PD-L1 regulated both CD8⁺ and CD4⁺ T-cells. To establish the contribution of PD-L1 and PD-L2 on regulatory B-cells (Bregs), infarct volumes were evaluated in male PD-L1- and PD-L2-deficient mice receiving IL-10⁺ B-cells 4h post-MCAO. PD-L2- but not PD-L1-deficient recipients of IL-10⁺ B-cells had markedly reduced infarct volumes, indicating a regulatory role of PD-L2 on Bregs. These results imply that PD-L1 and PD-L2 differentially control induction of T- and Breg-cell responses after MCAO, thus suggesting that selective targeting of PD-L1 and PD-L2 might represent a valuable therapeutic strategy in stroke.

Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice

Clinical stroke induces inflammatory processes leading to cerebral and splenic injury and profound peripheral immunosuppression. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B-cells led to larger infarct volumes and CNS damage after middle cerebral artery occlusion (MCAO) that could be prevented by transfer of IL-10(+) B-cells. The purpose of this study was to determine if the beneficial immunoregulatory effects on MCAO of the IL-10(+) B-cell subpopulation also extends to B-cell-sufficient mice that would better represent stroke subjects. CNS inflammation and infarct volumes were evaluated in male C57BL/6J (WT) mice that received either RPMI or IL-10(+) B-cells and underwent 60 min of middle cerebral artery occlusion (MCAO) followed by 96 h of reperfusion. Transfer of IL-10(+) B-cells markedly reduced infarct volume in WT recipient mice when given 24 h prior to or 4 h after MCAO. B-cell protected (24 h pre-MCAO) mice had increased regulatory subpopulations in the periphery, reduced numbers of activated, inflammatory T-cells, decreased infiltration of T-cells and a less inflammatory milieu in the ischemic hemispheres of the IL-10(+) B-cell-treated group. Moreover, transfer of IL-10(+) B-cells 24 h before MCAO led to a significant preservation of regulatory immune subsets in the IL-10(+) B-cell protected group presumably indicating their role in immunomodulatory mechanisms, post-stroke. Our studies are the first to demonstrate a major immunoregulatory role for IL-10(+) regulatory B-cells in preventing and treating MCAO in WT mice and also implicating their potential role in attenuating complications due to post-stroke immunosuppression.

Abstract W P92: Preclinical Evaluation of Recombinant T-cell Receptor Ligand RTL1000 as a Therapeutic Agent in Stroke

Objective: RTL1000, a partial human MHC molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DR2 transgenic mice expressing the human MHC class II allele. In this study, we characterized the therapeutic window of RTL1000. We then determined if RTL1000 efficacy is altered when combined with t-PA, a standard therapy for stroke, and if it affords long-term neurobehavioral functional improvement after stroke in mice.

Methods: Male DR2 mice underwent 60 min of intraluminal MCA occlusion (MCAO). RTL1000 (100 μg) or vehicle (100 μl) was given S.C. at 4, 6 or 8 h after MCAO, followed by 3 daily S.C. injections. t-PA (10 mg/kg) or vehicle was infused I.V. over 30 min starting at 15 min into ischemia. Brains were collected at either 24 or 96 h of reperfusion. Cortical, striatal and hemispheric infarcts were measured after staining with 2, 3, 5-triphenyltetrazolium chloride. Behavioral testing neuroscore, open field, paw preference and novel object recognition was performed up to 28 days after MCAO.

Results: RTL1000 significantly reduced infarct size when administered at 4 and 6, but not 8 h after MCAO. Protection was more robust when RTL1000 was given at 4 h, and was limited to cortex when first administration was delayed for 6 h. When administered alone, t-PA reduced infarct size when measured at 24 but not 96 h after MCAO. Importantly, RTL1000 alone reduced infarct size at 96 h after MCAO, and the addition of t-PA did not reduce its ability to protect against ischemic injury. Behavioral testing showed RTL1000 had no effect on acute cognitive impairment on day 7, but improved long term cognitive outcome 28 days after MCAO.

Conclusions: RTL1000 is protective against ischemic stroke with a therapeutic window of up to 6 h. Protection by RTL1000 is preserved in the presence of t-PA, is long-lasting and improves neurobehavioral functional outcomes after experimental cerebral ischemia.

Abstract T P221: Effect of CD4 And CD8 T Lymphocytes on Infarct Volume Following Experimental Stroke in Male Splenectomized Mice

We have previously shown profound splenic activation by 6 hours following experimental stroke, resulting in rapid and widespread increased production of inflammatory factors by basal and activated splenocytes in male mice. Our lab and others have also shown a subsequent extensive loss of lymphocytes and increased lymphocyte apoptosis in spleen 12 hours after experimental stroke. Lastly, we and others have shown that splenic immunocytes can contribute to increased brain inflammation and infarct volume. However, it is unclear which splenic immunocyte populations may contribute to the evolving ischemic brain injury. Using a mouse splenectomy model and adoptive cell transfer protocols, we evaluated the effect of different splenic immunocyte populations, specifically CD4 and CD8 T lymphocytes, on infarct volume. Male C57BL/6J mice were splenectomized 14 days before experimental stroke and treated 24 hours before experimental stroke with either vehicle (saline), CD4 T lymphocytes, or CD8 T lymphocytes obtained from GFP reporter mice. Each mouse (n=8-10 per group) then underwent 60 minutes of middle cerebral artery occlusion via intraluminal filament. All mice were euthanized and brains collected at 96 hours of reperfusion. Infarct volume (% corrected contralateral structure) was determined by image analysis of coronal brain slices stained with 2,3,5-triphenyltetrazolium chloride. Adoptive transfer of GFP positive CD4 (cortex, 44±3%; striatum, 50±2%) or CD8 (cortex, 48±2%; striatum, 53±3%) T lymphocytes in splenectomized male mice did not alter infarct volume compared to vehicle-treated (cortex, 38±4%; striatum, 42±5%) splenectomized males (cortex, p=0.140; striatum, p=0.143). Although adding back CD4 or CD8 T lymphocytes did not appear to alter infarct volume, these immunocyte populations are comprised of both inflammatory and regulatory subtypes. Thus, future studies will evaluate the effect of different CD4 and CD8 subpopulations on ischemic brain outcomes. This study was supported by National Institutes of Health grant NS076013.

Abstract T P210: Splenectomy Attenuates Sex Differences in Infarct Volume Following Experimental Stroke in Mice

It is now increasingly clear that human stroke can have other serious consequences besides brain damage that can impact on patient survival and recovery. For example, many stroke patients succumb to CNS injury-induced immunodepression and fatal infections. Our prior work suggests that evolving cerebral ischemic injury elicits a cycle of injury from brain-to-spleen-to-brain that is strongly influenced by sex. We determined if splenic immunocytes are important in contributing to sex differences in post-ischemic brain injury. Male and female C57BL/6J mice were splenectomized 14 days before experimental stroke. Male and female mice with or without splenectomy (n=9-10 per group) then underwent 60 min of middle cerebral artery occlusion (MCAO) via intraluminal filament. Laser-Doppler flowmetry (LDF) was used to monitor cortical perfusion. All mice were euthanized and brains collected at 96 hours of reperfusion. Infarct volume (% corrected contralateral structure) was determined by image analysis of coronal brain slices stained with 2,3,5-triphenyltetrazolium chloride. Mean arterial blood pressure (MABP), blood gases (pH, P a O 2 , P a CO 2 ), and blood glucose were measured at 30 min MCAO and at 15 min of reperfusion in separate groups of male and female mice with or without splenectomy (n=5 per group). Relative LDF changes (% baseline), MABP, blood gases, and blood glucose during and after MCAO were comparable among the experimental groups. We observed that infarct volume in females (cortex, 41±4%; striatum, 55±6%) was smaller ( P <0.05) compared to males (cortex, 52±3%; striatum, 75±3%) at 96 hours of reperfusion. However, no differences (cortex, P =0.313; striatum, P =0.601) in infarct volume were seen between splenectomized male (cortex, 43±4%; striatum, 51±7%) and female (cortex, 38±4%; striatum, 46±5%) mice. Our data suggest that removal of all splenocyte lineages via splenectomy attenuates sex differences in post-ischemic brain injury. Future studies will evaluate the role of different splenic immunocyte subsets, such as T or B lymphocytes, on male vs. female ischemic brain outcomes. This study was supported by National Institutes of Health grant NS076013.

PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1

Background

Stroke severity is worsened by recruitment of inflammatory immune cells into the brain. This process depends in part on T cell activation, in which the B7 family of co-stimulatory molecules plays a pivotal role. Previous studies demonstrated more severe infarcts in mice lacking programmed death-1 (PD-1), a member of the B7 family, thus implicating PD-1 as a key factor in limiting stroke severity. The purpose of this study was to determine if this protective effect of PD-1 involves either of its ligands, PD-L1 or PD-L2.

Methods

Central nervous system (CNS) inflammation and infarct volume were evaluated in male PD-L1 and PD-L2 knockout (^-/-) mice undergoing 60 minutes of middle cerebral artery occlusion (MCAO) followed by 96 hours of reperfusion and compared to wild-type (WT) C57BL/6J mice.

Results

PD-L1^-/- and PD-L2^-/- mice had smaller total infarct volumes compared to WT mice. The PD-L1^-/- and to a lesser extent PD-L2^-/- mice had reduced levels of proinflammatory activated microglia and/or infiltrating monocytes and CD4⁺ T cells in the ischemic hemispheres. There was a reduction in ischemia-related splenic atrophy accompanied by lower activation status of splenic T cells and monocytes in the absence of PD-L1, suggesting a pathogenic rather than a regulatory role for both PD-1 ligands (PD-Ls). Suppressor T cells (IL-10-producing CD8⁺CD122⁺ T cells) trafficked to the brain in PD-L1^-/- mice and there was decreased expression of CD80 on splenic antigen-presenting cells (APCs) as compared to the WT and PD-L2^-/- mice.

Conclusions

Our novel observations are the first to implicate PD-L1 involvement in worsening outcome of experimental stroke. The presence of suppressor T cells in the right MCAO-inflicted hemisphere in mice lacking PD-L1 implicates these cells as possible key contributors for controlling adverse effects of ischemia. Increased expression of CD80 on APCs in WT and PD-L2^-/- mice suggests an overriding interaction leading to T cell activation. Conversely, low CD80 expression by APCs, along with increased PD-1 and PD-L2 expression in PD-L1^-/- mice suggests alternative T cell signaling pathways, leading to a suppressor phenotype. These results suggest that agents (for example antibodies) that can target and neutralize PD-L1/2 may have therapeutic potential for treatment of human stroke.

IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke

Clinical stroke induces inflammatory processes leading to cerebral injury. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B-cells led to larger infarct volumes and increased numbers of activated T-cells, monocytes and microglial cells in the brain, thus implicating a regulatory role of B-cell subpopulations in limiting CNS damage from stroke. The aim of this study was to determine whether the IL-10-producing regulatory B-cell subset can limit CNS inflammation and reduce infarct volume following ischemic stroke in B-cell deficient (μMT(-/-)) mice. Five million IL-10-producing B-cells were obtained from IL-10-GFP reporter mice and transferred i.v. to μMT(-/-)mice. After 24 h following this transfer, recipients were subjected to 60 min of middle cerebral artery occlusion (MCAO) followed by 48 h of reperfusion. Compared to vehicle-treated controls, the IL-10(+) B-cell-replenished μMT(-/-)mice had reduced infarct volume and fewer infiltrating activated T-cells and monocytes in the affected brain hemisphere. These effects in CNS were accompanied by significant increases in regulatory T-cells and expression of the co-inhibitory receptor, PD-1, with a significant reduction in the proinflammatory milieu in the periphery. These novel observations provide the first proof of both immunoregulatory and protective functions of IL-10-secreting B-cells in MCAO that potentially could impart significant benefit for stroke patients in the clinic.

PD-1 interaction with PD-L1 but not PD-L2 on B cells mediates protective effects of estrogen against EAE (P5176)

Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen (E2) and estriol (E3). In fact, treatment with relatively low doses of E2 can protect against clinical and histological signs of MOG-35-55 induced experimental autoimmune encephalomyelitis (EAE) through mechanisms involving PD-1, PD-L1 and B cells. The current study sought to determine more specifically the contribution of PD-L1 and PD-L2 on B cells in E2-mediated protection. Thus, WT, PD-L1 knockout (KO) and PD-L2 KO mice were implanted with E2 pellets prior to EAE induction and the disease course was followed. Unlike PD-L2 KO mice that were fully protected against EAE after E2 treatment, E2-implanted PD-L1 KO mice were fully susceptible to EAE, with increased numbers of proliferating Th1/Th17 cells in the periphery and severe cellular infiltration and active demyelination in the CNS. Moreover, transfer of B cells from MOG-immunized PD-L1 KO or PD-L2 KO donors into E2-preconditioned B cell deficient μMT-/- recipient mice revealed significantly reduced E2-mediated protection against EAE in recipients of PD-L1 KO B cells, but complete protection in recipients of PD-L2 KO B cells. We conclude that PD-1 interaction with PD-L1 but not PD-L2 on B cells is crucial for E2-mediated protection in EAE and that strategies that enhance PD-1/PD-L1 interactions might potentiate E2 treatment effects in EAE and MS.

Dendritic cells are the major antigen presenting cells in inflammatory lesions of murine mycoplasma respiratory disease and contribute to disease severity (P3306)

Mycoplasmas cause chronic respiratory diseases in animals and humans, and vaccine development has been problematic. T cell responses were shown to confer protection as well as promote immunopathology in murine mycoplasma pneumonia. Because T cells play a critical role, the role of antigen presenting cells (APC) was examined as they likely influence either an increase in disease severity or promote protective immunity. The roles of APC, such as dendritic cells (DC) and macrophages, in mycoplasma disease are currently unknown. In this study, we examined the ability pulmonary APC populations and their contribution to T cell responses during disease pathogenesis. Both macrophages and DC increased in the lungs of mice after infection. These cell populations showed different patterns of cytokine mRNA expression, supporting the idea that these cells have different impacts on immunity in response to infection. In fact, DC from the lungs of infected mice were most capable of stimulating mycoplasma-specific T helper (Th) cell responses in vitro. In vivo, DC cells were co-localized with Th cells in inflammatory lesions in the lungs of mycoplasma-infected mice. Intratracheal inoculation of mycoplasma antigen-pulsed DC resulted in increased disease severity after subsequent infection. Thus, DC appear to be the major APC population responsible for pulmonary T cell stimulation in mycoplasma-infected mice, and these DC likely contribute to responses impacting disease pathogenesis.

Opposing roles of PD-1 and PD-L in modulating CNS inflammation and infarct volume following experimental stroke in mice (P1012)

Stroke severity is worsened by recruitment of inflammatory immune cells into the brain. This process depends in part on T cell activation, in which the B7 family of co-stimulatory molecules plays a pivotal role. Previous studies demonstrated more severe infarcts in mice lacking Programmed Death-1 (PD-1), a member of the B7 family, thus implicating PD-1 as a key factor in limiting stroke severity. The purpose of this study was to determine if this protective effect of PD-1 involves either of its ligands, PD-L1 and PD-L2. Thus, CNS inflammation and stroke severity were evaluated in male PD-L1 and PD-L2 knockout (KO) mice undergoing 60 min middle cerebral artery occlusion (MCAO) followed by 96 h reperfusion. Unexpectedly, PD-L1 KO and to a lesser extent PD-L2 KO mice had reduced levels of activated microglia and infiltrating monocytes and total infarct volume compared to wild-type mice, as well as reduced splenic atrophy and MHC class II expression, suggesting a pathogenic rather than a regulatory role for both PD-ligands. Both positive and negative regulatory roles have been suggested for the PD-ligands in context of various diseases and our novel observations indicate that PD-L1 and PD-L2 might have proinflammatory functions independent of PD-1 binding that worsen stroke outcome. These results suggest the possibility of using antibodies to PD-L1/2 as a potential treatment for human stroke patients.

IL-10-producing B cells limit CNS inflammation and infarct volume after experimental stroke in mice (P1090)

Clinical stroke induces inflammatory processes leading to cerebral injury. IL-10 expression is elevated during major CNS diseases and limits inflammation in the brain. Recent evidence demonstrated that absence of B cells led to larger infarct volumes and increased numbers of activated T cells, monocytes and microglial cells in the brain, thus implicating a regulatory role of B cell subpopulations in limiting CNS damage from stroke. The aim of this study was to determine whether the IL-10-producing regulatory B cell subset can limit CNS inflammation and reduce infarct volume following ischemic stroke in B-cell deficient (μMT-/-) mice. Five million IL-10-producing B cells were obtained from IL-10-GFP reporter mice and transferred i.v. to μMT-/- mice. After 24 h from this transfer, recipients were subjected to 60 min of middle cerebral artery occlusion (MCAO) followed by 48 h of reperfusion. Compared to vehicle-treated controls, the IL-10+ B-cell-replenished μMT-/- mice had reduced infarct volume and fewer infiltrating activated T cells and monocytes in the affected brain hemisphere. These effects in CNS were accompanied by significant increases in regulatory T cells and expression of the co-inhibitory receptor, PD-1, in the periphery. These novel observations demonstrate both immunoregulatory and protective functions of IL-10-secreting B cells in MCAO that potentially could impart significant benefit for stroke patients in the clinic.

Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells

It is now well accepted that sex hormones have immunoregulatory activity and may prevent exacerbations in multiple sclerosis during pregnancy. Our previous studies demonstrated that oestrogen (17β-oestradiol; E(2) ) protection against experimental autoimmune encephalomyelitis (EAE) is mediated mainly through oestrogen receptor-α (ERα) and the membrane receptor G-protein-coupled receptor 30 (GPR30) and is abrogated in the absence of B cells and the co-inhibitory receptor, Programmed Death-1 (PD-1). To critically evaluate the cell source of the E2 and PD-1 co-inhibitory pathways in EAE regulation, we assessed the requirement for ERs on transferred B cells and downstream effects on expression of PD-1/PD-ligand on CD4+ Foxp3+ regulatory T (Treg) cells in B-cell-replenished, E2-treated B-cell-deficient (μMT-/-) mice with EAE. The results clearly demonstrated involvement of ERα and GPR30 on transferred B cells that mediated the protective E2 treatment effect on EAE and further showed an E2-mediated B-cell-dependent up-regulation of PD-1 on CD4+ Foxp3+ Treg cells. These findings identify regulatory B-cell populations as key players in potentiating Treg-cell activity during E2-mediated protection against EAE.

Dendritic cells are the major antigen presenting cells in inflammatory lesions of murine Mycoplasma respiratory disease

Mycoplasmas cause chronic respiratory diseases in animals and humans, and to date, development of vaccines have been problematic. Using a murine model of mycoplasma pneumonia, lymphocyte responses, specifically T cells, were shown to confer protection as well as promote immunopathology in mycoplasma disease. Because T cells play such a critical role, it is important to define the role of antigen presenting cells (APC) as these cells may influence either exacerbation of mycoplasma disease pathogenesis or enhancement of protective immunity. The roles of APC, such as dendritic cells and/or macrophages, and their ability to modulate adaptive immunity in mycoplasma disease are currently unknown. Therefore, the purpose of this study was to identify individual pulmonary APC populations that may contribute to the activation of T cell responses during mycoplasma disease pathogenesis. The present study indeed demonstrates increasing numbers of CD11c⁻ F4/80⁺ cells, which contain macrophages, and more mature/activated CD11c⁺ F4/80⁻ cells, containing DC, in the lungs after infection. CD11c⁻ F4/80⁺ macrophage-enriched cells and CD11c⁺ F4/80⁻ dendritic cell-enriched populations showed different patterns of cytokine mRNA expression, supporting the idea that these cells have different impacts on immunity in response to infection. In fact, DC containing CD11c⁺ F4/80⁻ cell populations from the lungs of infected mice were most capable of stimulating mycoplasma-specific CD4⁺ Th cell responses in vitro. In vivo, these CD11c⁺F4/80⁻ cells were co-localized with CD4⁺ Th cells in inflammatory infiltrates in the lungs of mycoplasma-infected mice. Thus, CD11c⁺F4/80⁻ dendritic cells appear to be the major APC population responsible for pulmonary T cell stimulation in mycoplasma-infected mice, and these dendritic cells likely contribute to responses impacting disease pathogenesis.

Abstract WMP68: Loss Of Programmed Cell Death Ligand 1 And 2 Reduces Total Infarct Volume In Male Mice Following Experimental Stroke

The programmed cell death 1 receptor (PD-1) is an immunoglobulin superfamily member whose expression is induced in activated T cells, B cells, natural killer cells and monocytes. Binding of PD-1 to either of its two known ligands, programmed cell death ligand 1 and 2 (PD-L1 and PD-L2), induces inhibitory signals that regulate peripheral T cell tolerance and immune homeostasis. We have shown increased PD-1 expression in brain macrophages and glia as well as increased PD-L1 and PD-L2 expression in peripheral and brain B cells in mice after experimental stroke. Furthermore, we have observed increased infarct volume in PD-1 deficient mice, thus potentially implicating the PD-1/PD-L co-inhibitory pathway in post-stroke CNS inflammation. Using PD-L1 and PD-L2 deficient mice, we determined if PD-L1 or PD-L2 was also important in modulating stroke infarct volume. Young adult male wild-type (WT; n=11) and PD-L1 (n=9) and PD-L2 (n=12) knockout (KO) mice underwent 60 min of middle cerebral artery occlusion via intraluminal filament. Laser-Doppler flowmetry was used to monitor cortical perfusion. All mice were euthanized and brains collected at 96 h of reperfusion. Total infarct volume (% corrected contralateral hemisphere) was determined by image analysis of coronal brain slices stained with 2,3,5-triphenyltetrazolium chloride (TTC). Relative laser Doppler flowmetry changes (% baseline) during and after middle cerebral artery occlusion were equivalent among groups. Compared to male WT mice (WT vs. KO), genetic deletion of either PD-L1 (51+3% vs. 20+5%; p<0.001) or PD-L2 (51+3% vs. 35+4%; p=0.007) reduced total infarct volume. We also observed that total infarct volume was smaller in PD-L1 vs. PD-L2 KO mice (20+5% vs. 35+4%; p=0.017). Our findings along with our previous work in PD-1 deficient mice suggest that ligands other than PD-L1 or PD-L2 might be involved with PD-1 signaling in ischemic brain and that PD-L1 and PD-L2 might have other functions independent of PD-1 binding affecting infarct volumes. Future studies will evaluate the roles of PD-1, PD-L1, and PD-L2 in regulatory immune cell subsets that affect ischemic brain outcomes. This study was supported by National Institutes of Health grant NS075887.

PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE

Increased remissions in multiple sclerosis (MS) during late pregnancy may result from high levels of sex steroids such as estrogen and estriol. Estrogen (E2=17β-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear. Treatment with relatively low doses of E2 can protect against clinical and histological signs of MOG-_35-55 induced EAE through mechanisms involving the PD-1 coinhibitory pathway and B-cells. The current study evaluated the contribution of PD-1 ligands, PD-L1 and PD-L2, on B-cells in E2-mediated protection against EAE in WT, PD-L1^-/- and PD-L2^-/- mice. Unlike PD-L2^-/- mice that were fully protected against EAE after E2 treatment, E2-implanted PD-L1^-/- mice were fully susceptible to EAE, with increased numbers of proliferating Th1/Th17 cells in the periphery and severe cellular infiltration and demyelination in the CNS. Moreover, transfer of B-cells from MOG-immunized PD-L1^-/- or PD-L2^-/- donors into E2-preconditioned B-cell deficient μMT^-/- recipient mice revealed significantly reduced E2-mediated protection against EAE in recipients of PD-L1^-/- B-cells, but near-complete protection in recipients of PD-L2^-/- B-cells. We conclude that PD-1 interaction with PD-L1 but not PD-L2 on B-cells is crucial for E2-mediated protection in EAE and that strategies that enhance PD-1/PD-L1 interactions might potentiate E2 treatment effects in MS.

Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice

Recent evidence emphasizes B-cells as a major regulatory cell type that plays an important role in limiting the pathogenic effects of ischemic stroke. The aim of the current study was to extend this initial observation to specifically examine the infiltration of regulatory B-cells and to determine if the effect of B-cells to limit the inflammatory response to cerebral ischemia is mediated by their action centrally or peripherally. Our data demonstrate the increased presence of a regulatory B-cell subset in the affected hemisphere of wild-type mice after middle cerebral artery occlusion (MCAO). We further explored the use of a novel method of stereotaxic cell delivery to bypass the blood brain barrier (BBB) and introduce CD19(+) B-cells directly into the striatum as compared to peripheral administration of B-cells. Infarct volumes after 60 minutes of MCAO and 48 hours of reperfusion were determined in B-cell deficient μMT( -/- ) mice with and without replacement of either B-cells or medium. Infarct size was significantly decreased in cerebral cortex after intrastriatal transfer of 100,000 B-cells to μMT(-/-) mice vs. controls, with a comparable effect on infarct size as obtained by 50 million B-cells transferred intraperitoneally. These findings support the hypothesis that B-cells play a protective role against ischemic brain injury, and suggest that B-cells may serve as a novel therapeutic agent for modulating the immune response in central nervous system inflammation after stroke.

GPR30 FORMS AN INTEGRAL PART OF E2-PROTECTIVE PATHWAY IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

A major focus of our laboratory has been an in-depth evaluation as to how estrogens exert a pronounced protective effect on clinical and histological disease in the animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). An important issue regarding their therapeutic application has been the undesirable estrogenic side effects thought to be mediated primarily through 17β-estradiol (E2) binding to intracellular estrogen receptor alpha (ERα). With the discovery and characterization of GPR30 as the putative membrane estrogen receptor, we sought to study whether signaling through GPR30 was sufficient to mediate protection against EAE without engagement of ERα. Treatment of EAE in WT mice with G-1, a selective GPR30 agonist, retained estradiol's ability to protect against clinical and histological EAE without estrogenic side effects. G-1 treatment deviated cytokine profiles and enhanced suppressive activity of CD4(+)Foxp3(+) Treg cells through a GPR30- and programmed death 1 (PD-1)-dependent mechanism. This novel finding was indicative of the protective effect of GPR30 activation in EAE and provides a strong foundation for the clinical application of GPR30 agonists such as G-1 in MS. However, future studies are needed to elucidate cross-signaling and evaluate possible additive effects of combined signaling through both GPR30 and ER-α. Deciphering the possible mechanism of involvement of GPR30 in estrogen-mediated protection against EAE may result in lowering treatment doses of E2 and GPR30 agonists that could minimize risks and maximize immunoregulation and therapeutic effects in MS. Alternatively, one might envision using E2 derivatives with reduced estrogenic activity alone or in combination with GPR30 agonists as therapies for both male and female MS patients.

Indispensable role of B cells in mediating protective effects of estrogen against EAE (167.20)

Increased remissions in multiple sclerosis (MS) during pregnancy suggest elevated levels of sex steroids exert immunoregulatory activity. Estrogen (E2) protects against experimental autoimmune encephalomyelitis (EAE), but its mechanism is unclear. Depletion of B cells prior to induction of EAE exacerbates disease severity. The purpose of this study was to evaluate role of B cells in E2-induced protection against EAE. B cell deficient (μMT-/-) mice were used to study whether absence of B cells abrogated E2-mediated protection against EAE. Mice were sham-treated or implanted with E2 pellets, 8 days prior to immunization with mMOG35-55 peptide with CFA/Ptx and the disease course was followed. EAE-protective effects of E2 were totally lost in μMT-/- mice, with no reduction in disease severity, cellular infiltration or pro-inflammatory factors in CNS compared to controls. E2 treatment of WT mice selectively increased percentage expression of PD-L1 on B cells and IL-10-producing CD1dhighCD5+ regulatory B cells. Direct treatment of B cells with E2 significantly reduced proliferation of MOG35-55-specific T cells that required ERα. Thus, B cells play an indispensable role in E2-mediated protection involving direct E2 effects on regulatory B cells. E2-primed B cells may play a crucial regulatory role in MS and have strong implications in current MS therapies that cause B cell-depletion.

Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells

Increased remissions in multiple sclerosis (MS) during pregnancy suggest that elevated levels of sex steroids exert immunoregulatory activity. Estrogen (E2=17β-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear. Studies demonstrate that depletion of B cells prior to induction of EAE exacerbates disease severity, implicating regulatory B cells. We thus evaluated pathogenic and E2-induced protective mechanisms in B-cell-deficient (μMT(-/-)) mice. EAE-protective effects of E2 were abrogated in μMT(-/-) mice, with no reduction in disease severity, cellular infiltration or pro-inflammatory factors in the central nervous system compared to untreated controls. E2 treatment of WT mice selectively upregulated expression of PD-L1 on B cells and increased the percentage of IL-10-producing CD1d(high) CD5(+) regulatory B cells. Upregulation of PD-L1 was critical for E2-mediated protection since E2 did not inhibit EAE in PD-L1(-/-) mice. Direct treatment of B cells with E2 significantly reduced proliferation of MOG(35-55)-specific T cells that required estrogen receptor-α (ERα). These results demonstrate, for the first time, a requirement for B cells in E2-mediated protection against EAE involving direct E2 effects on regulatory B cells mediated through ERα and the PD-1/PD-L1 negative co-stimulatory pathway. E2-primed B cells may represent an important regulatory mechanism in MS and have strong implications for women receiving current MS therapies that cause B-cell depletion.

Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against mycoplasma respiratory disease

For vaccine development, it is critical to understand the regulatory mechanisms determining resistance and immunopathology against mycoplasma respiratory diseases. The present study evaluated the contribution of the polarizing cytokines interferon gamma (IFN-gamma) and interleukin 4 (IL-4) in the regulation of mycoplasma-specific immunity. The absence of a single cytokine (either IFN-gamma or IL-4) uniquely altered the expression of multiple chemokines and cytokines in the lungs of uninfected mice and influenced responses to mycoplasma infection. Most importantly, prior nasal-pulmonary immunization of IFN-gamma(-/-) mice led to exacerbated mycoplasma disease, whereas immunized IL-4(-/-) mice were dramatically more resistant than wild-type mice. Helper T cell type 2 responses in IFN-gamma(-/-) mice corresponded to immunopathologic reactions that developed after mycoplasma infection or immunization. Thus, adaptive immunity clearly can independently promote either protection or immunopathology against mycoplasma infection, and optimal vaccination appears to be dependent on promoting protective IFN-gamma-dependent networks (perhaps helper T cell type 1 responses) while minimizing the effect of IL-4-mediated responses, which dampen the generation of protective immunity.

NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization

The purpose of the present study was to determine the impact of NK cells on the development of protective adaptive immunity in response to nasal-pulmonary immunization against mycoplasma. Depletion of NK cells before nasal-pulmonary immunization enhanced resistance to mycoplasma respiratory infection. The effect of NK cells on the generation of protective immunity in lungs was dependent on lymphoid cells, as immunization of either SCID mice or immunocompetent mice depleted of CD4(+) T cells did not demonstrate any increased resistance in the presence or absence of NK cells. The presence of NK cells at the time of nasal-pulmonary immunization modulated mycoplasma-specific cytokine responses in lungs and lower respiratory nodes. In particular, NK cells skewed the mycoplasma-specific T cell cytokine responses in the draining lymph nodes to higher IL-4, IL-13, and IL-17 while lowering IFN-gamma responses. Adoptive transfer of total lung lymphocytes isolated from immunized mice into naive mice led to a significant reduction in the mycoplasma numbers in lungs, and the resistance was greater if cells were obtained from immunized mice that were depleted of NK cells. Similar results were obtained if purified B cells, T cells, or CD4(+) T cells were used. Interestingly, this is the first time that a favorable role of functional CD4(+) T cells in mediating protection in mycoplasma respiratory disease was demonstrated. Thus, NK cells can influence the responses of multiple lymphocyte populations capable of mediating resistance to mycoplasma infection.

A novel IL-17-dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection

Immune responses to pathogens occur within the context of current and previous infections. Cross protection refers to the phenomena where infection with a particular pathogen provides enhanced resistance to a subsequent unrelated pathogen in an antigen-independent manner. Proposed mechanisms of antigen-independent cross protection have involved the secretion of IFN-gamma, which activates macrophages, thus providing enhanced innate immunity against the secondary viral or bacterial pathogen. Here we provide evidence that a primary infection with the chronic respiratory pathogen, Mycoplasma pulmonis, provides a novel form of cross protection against a secondary infection with Listeria monocytogenes that is not mediated by IFN-gamma, but instead relies upon IL-17 and mobilization of neutrophils. Mice infected with M. pulmonis have enhanced clearance of L. monocytogenes from the spleen and liver, which is associated with increased numbers of Gr-1(+)CD11b(+) cells and higher levels of IL-17. This enhanced clearance of L. monocytogenes was absent in mice depleted of Gr-1(+) cells or in mice deficient in the IL-17 receptor. Additionally, both the IL-17 receptor and neutrophils were essential for optimal clearance of M. pulmonis. Thus, a natural component of the immune response directed against M. pulmonis was able to enhance clearance of L. monocytogenes.

Novel role of NK cells in the development of adaptive immunity against mycoplasma respiratory disease (46.23)

A complex balance between the detrimental and beneficial effects of immunity determines the course of mycoplasma respiratory infection. NK cells were shown to dampen innate immunity in the lungs. The purpose of this study was to determine if NK cells similarly impacted the development of adaptive immunity against mycoplasma disease. Anti-asialoGM1 Ab was used to transiently deplete NK cells prior to nasal-pulmonary immunization with mycoplasma membrane Ag. Unimmunized and mice receiving only anti-asialoGM1 Ab served as controls. The treatment was repeated 7d later and the mice were challenged on day 14 with M. pulmonis. DX5+ NK cell numbers returned to normal by day 14. Colony forming units (CFUs) in lungs and nasal passages were determined 3, 7 and 14d later.

There was a significant decrease (&gt;1 log) in CFUs in the NK cell depleted, immunized mice as compared to immunized or control mice. No such effect was seen in SCID mice, indicating adaptive immunity was affected. Further support that the protection rendered due to depletion of NK cells prior to immunization, was lymphocyte-mediated, was demonstrated when protection was shown to be adoptively transferred to naïve mice using total lung lymphocytes, purified T and/or Non T cells.

In conclusion, NK cells dampen the generation of protective adaptive immunity associated with nasal-pulmonary immunization, and this effect is on the generation of lymphoid cell mediated response. These results should provide insights into approaches to generate optimal protective immunity against mycoplasma respiratory diseases.

Immunomodulatory activity of alcoholic extract of Mangifera indica L. in mice

Mangifera indica Linn, a plant widely used in the traditional medicinal systems of India, has been reported to possess antiviral, antibacterial and anti-inflammatory activities. In the present study, the alcoholic extract of stem bark of Mangifera indica Linn (Extract I containing mangiferin 2.6%), has been investigated for its effect on cell mediated and humoral components of the immune system in mice. Administration of test extract I produced increase in humoral antibody (HA) titre and delayed type hypersensitivity (DTH) in mice. It is concluded that test extract I is a promising drug with immunostimulant properties.

Effect of some serotoninergic agents on the rectal temperature of the domestic fowl (Gallus domesticus)

The information currently available in the literature on the effects of serotonergic drugs on thermoregulation in the avian species is very scanty. Therefore, it was the objective in this project to study the influence of 5-hydroxytryptamine (5-HT), 5-hydroxytryptophan (5-HTP), benserazide, carbidopa (Mk 486), citalopram, cyproheptadine, methysergide, xylamidine, p-chlorophenylalanine (PCPA) and lysergic acid diethylamide (LSD-25) on the rectal temperature of young chicks. 5-hydroxytryptamine (0.8 mg/kg), produced significant dose-dependent hypothermia in young chicks. Similarly, 5-HTP (16 mg/kg) profoundly lowered the rectal temperature of young chicks. The hypothermic effect of 5-HTP was potentiated by benserazide (1.25-2.5 mg/kg). Pretreatment with carbidopa (50 mg/kg) potentiated 5-HTP induced hypothermia. Citalopram (5 mg/kg) significantly potentiated hypothermia induced by 5-HT. Pretreatment with PCPA (200 mg/kg, 24 hr previously) alone resulted in hyperthermia while the hypothermic effect of 5-HTP (16 mg/kg) was antagonised by pretreatment with PCPA. Cyproheptadine (1.25 mg/kg) antagonised the hypothermic effect of 5-HT (0.1 and 0.8 mg/kg). The antagonistic effect was weak when the chicks were pretreated with larger doses of cyproheptadine (i.e. 2.5-10 mg/kg). The hypothermia induced by 5-HT (0.8 mg/kg) was antagonised by smaller doses of methysergide (0.125-1.0 mg/kg) but potentiated by larger doses of methysergide (2.0 and 4.0 mg/kg). Xylamidine (1-2 mg/kg) alone induced hyperthermia and effectively antagonised hypothermia induced by 5-HT (0.8 mg/kg). D-Lysergic acid diethylamide (2.5-10 micrograms/kg) alone induced hypothermia. The interaction between LSD and 5-HT was dose-dependent and biphasic.(ABSTRACT TRUNCATED AT 250 WORDS)

Pharmacological effects of Synclisia scabrida alkaloid B on some isolated muscle preparations

Alkaloid B reversibly blocked the responses of rat diaphragm to electrically induced stimulations via the phrenic nerve. The alkaloid had no effect on the responses of the diaphragm elicited by direct electrical stimulation. The responses of frog rectus abdominis muscle to acetylcholine were inhibited by alkaloid B. Alkaloid B reversibly antagonised the responses of rabbit duodenum to exogenously applied acetylcholine. The contractile effect of oxytocin on rat uterus was specifically inhibited by alkaloid B. The effects of alkaloid B on isolated muscle preparations were concentration-dependent. However, the effect of dopamine and noradrenaline on rat vas deferens was not altered by alkaloid B.